The Biotech Bubble: When Stock Tips Meet Scientific Progress The recent price target increase for BioMarin Pharmaceutical Inc.
(NASDAQ:BMRN) by Evercore ISI has drawn attention to the company's promising research in treating rare diseases.
This upgrade to $120 is a vote of confidence, but it's worth examining whether this stock fits into a broader narrative about the intersection of biotech and finance.